NRXP Jan 2024 5.000 put
| Previous close | 4.6000 |
| Open | 4.6000 |
| Bid | 3.4000 |
| Ask | 5.0000 |
| Strike | 5.00 |
| Expiry date | 2024-01-19 |
| Day's range | 4.6000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 39 |
PR NewswireNRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Founder and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the Noble Capital Markets' 19th Annual Emerging Growth Investor Conference on Monday, December 4th, 2023, at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton, Fla.
- PR Newswire
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended September 30, 2023 and provided a business update. Given the volume of information discussed this quarter, we have issued this release in advance of our conference call to allow investors additional time to review.
- PR Newswire
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m. ET the sam
